RVU Ryvu Therapeutics S.A.
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial for the treatment of diffuse large b-cell lymphoma and acute myeloid leukemia. In addition, the company's early pipeline candidates include candidates in the areas of kinases, synthetic lethality, immunometabolism, and immuno-oncology. It has collaborations with BioNTech SE to advance small molecule programs to target immune modulation in cancer and other disease areas; Exelixis Inc. for the development of targeted therapies based on Ryvu's STING agonist technology. The company was formerly known as Selvita S.A. and changed its name to Ryvu Therapeutics S.A. in October 2019. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.…
Industry Peers
BiotechnologyKey Statistics
About Ryvu Therapeutics (WSE: RVU)
›
Ryvu Therapeutics (WSE: RVU) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 228 employees.
The shares were at 16.88 PLN on 19 November 2026, down 45.4% over 52 weeks. Its 52-week range is 13.64 PLN to 31.90 PLN: the price is 47.1% below the high and 23.8% above the low.
Its market capitalisation is 390.27M PLN.
Ryvu Therapeutics reports return on equity of -188.0%, an operating margin of -85.0% and revenue down 20.8% year over year.
Its debt exceeds its cash by 17.35M PLN, a debt-to-equity ratio of 1.33. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 29.90 PLN is 77.1% above the current price.